| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Accounts receivable | 0 | 5 | 15 | NaN |
| Cash and cash equivalents | 20 | 3 | 12 | 624 |
| Inventory | 63 | 63 | 485 | 486 |
| Current portion of notes receivable | 199 | 198 | 199 | 200 |
| Prepaid expenses and other current assets | 95 | 142 | 206 | 171 |
| Total current assets | 377 | 411 | 917 | 1,481 |
| Property, plant and equipment, net | NaN | NaN | 13 | 14 |
| Other intangible assets, net | 16,709 | 16,994 | 17,278 | 17,565 |
| Notes receivable | NaN | NaN | NaN | 0 |
| Total assets | 17,086 | 17,405 | 18,208 | 19,060 |
| Note payable, related party | NaN | NaN | 22,881 | 22,352 |
| Accounts payable | 374 | 347 | 576 | 554 |
| Accrued expenses | 210 | 194 | 336 | 266 |
| Due to related party | 1,103 | 621 | NaN | NaN |
| Total current liabilities | 1,687 | 1,162 | 23,793 | 23,172 |
| Deferred tax liability, net | 688 | 688 | 3,268 | 3,268 |
| Total liabilities | 2,375 | 1,850 | 27,061 | 26,440 |
| Preferred stock, 0.001 par value 100,000,000 shares authorized, 60,496,041 shares issued and outstanding (60,496,041 on december 31, 2024) liquidation value 0.001 per share, 60,496,041 aggregate. 60,496,041 on december 31, 2024) | NaN | NaN | 60 | 60 |
| Common stock, 0.001 par value 4,000,000,000 shares authorized, 107,821,231 shares issued and outstanding on march 31, 2026 (104,621,231 on december 31, 2025) | 108 | 105 | 12 | 12 |
| Additional paid-in capital | 63,150 | 62,011 | 42,871 | 42,870 |
| Accumulated deficit | -51,794 | -49,507 | -54,752 | -53,283 |
| Total stockholders equity of the company | 11,464 | 12,609 | -11,809 | -10,341 |
| Non-controlling interest in subsidiaries | 3,247 | 2,946 | 2,956 | 2,961 |
| Total stockholders equity | 14,711 | 15,555 | -8,853 | -7,380 |
| Total liabilities and stockholders equity | 17,086 | 17,405 | 18,208 | 19,060 |
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)